Table 1

Characteristics of the sample at time of index date

Total,
N=4457
(100%)
Acute treatment,*
N=3613
(81.1%)
Prophylactic treatment,*
N=477
(10.7%)
Both,*
N=367
(8.2%)
P value
Sex
 Males1393 (31.3)1121 (31.0)159 (33.3)113 (30.8)
 Females3064 (68.7)2492 (69.0)318 (66.7)254 (69.2)
Mean age±SD49.8±17.050.1±16.349.2±22.047.6±16.1
Age groups<0.001
 ≤29 years509 (11.4)366 (10.1)92 (19.3)51 (13.9)
 30–55 years2413 (54.1)2000 (55.4)195 (40.9)218 (59.4)
 ≥56 years1535 (34.4)1247 (34.5)190 (39.8)98 (26.7)
Type of patients' recruitment<0.001
 Migraine-specific treatment3939 (88.4)3338 (92.4)274 (57.4)327 (89.1)
 Hospital diagnosis of migraine518 (11.6)275 (7.6)203 (42.6)40 (10.9)
Comorbidities<0.001
 Autoimmune disease52 (1.2)37 (1.0)6 (1.3)9 (2.5)
 Chronic kidney disease48 (1.1)35 (1.0)10 (2.1)3 (0.8)
 COPD797 (17.9)651 (18.0)79 (16.6)67 (18.3)
 Diabetes361 (8.1)288 (8.0)49 (10.3)24 (6.5)
 Hypertension1485 (33.3)1178 (32.6)187 (39.2)120 (32.7)
Comedications<0.001
 Drugs for respiratory system717 (16.1)596 (16.5)63 (13.2)58 (15.8)
 Anticonvulsants323 (7.2)243 (6.7)51 (10.7)29 (7.9)
 Antidepressants435 (9.8)322 (8.9)64 (13.4)49 (13.4)
 Cardiovascular1592 (35.7)1276 (35.3)182 (38.2)134 (36.5)
Polypharmacy<0.001
 0–4 drugs (no polypharmacy)2258 (50.7)1838 (50.9)241 (50.5)179 (48.8)
 5–9 drugs (polypharmacy)1330 (29.8)1070 (29.6)150 (31.4)110 (30.0)
 ≥10 drugs (excessive polypharmacy)869 (19.5)705 (19.5)86 (18.0)78 (21.3)
  • *Acute cohort includes incident patients who have received a prescription of acute medication for migraine treatment 60 days after their index date. Prophylactic cohort includes incident patients who have received a prescription of prophylactic medication for migraine treatment 60 days after their index date. Both includes incident patients who have received a prescription of both acute and prophylactic medications for migraine treatment 60 days after their index date.

  • COPD, chronic obstructive pulmonary disease.